Clinical trial
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza…
NCT00434733 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00434733 |
|---|---|
| Title | Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects |
| Official title | A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Vaccines Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Pandemic influenza vaccine |
| Enrollment | 4,400 |
| Start date | Jan 1, 2007 |
| First posted | Feb 13, 2007 |
| Last update posted | Apr 24, 2008 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: